FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200415204> ?p ?o ?g. }

• W4200415204 endingPage "47" @default.
• W4200415204 startingPage "38" @default.
• W4200415204 abstract "<b><i>Introduction:</i></b> Cabozantinib, an inhibitor of MET, AXL, and VEGF receptors, significantly improved overall survival (OS) and progression-free survival (PFS) versus placebo in patients with previously treated advanced hepatocellular carcinoma (HCC). In this exploratory analysis, outcomes were evaluated according to plasma biomarker levels. <b><i>Methods:</i></b> Baseline plasma levels were evaluated for MET, AXL, VEGFR2, HGF, GAS6, VEGF-A, PlGF, IL-8, EPO, ANG2, IGF-1, VEGF-C, and c-KIT for 674/707 randomized patients; and Week 4 levels were evaluated for MET, AXL, VEGFR2, HGF, GAS6, VEGF-A, PlGF, IL-8, and EPO for 614 patients. OS and PFS were analyzed by baseline levels as dichotomized or continuous variables and by on-treatment changes at Week 4 as continuous variables; biomarkers were considered potentially prognostic if <i>p</i> &#x3c; 0.05 and predictive if <i>p</i> &#x3c; 0.05 for the interaction between treatment and the biomarker. Multivariable analyses adjusting for clinical covariates were also performed. <b><i>Results:</i></b> In the placebo group, high levels of MET, HGF, GAS6, IL-8, and ANG2 and low levels of IGF-1 were associated with shorter OS in univariate and multivariable analyses; these associations were also observed for MET, IL-8, and ANG2 in the cabozantinib group. Hazard ratios for OS and PFS favored cabozantinib over the placebo at low and high baseline levels for all biomarkers. No baseline biomarkers were predictive of a treatment benefit. Cabozantinib promoted pharmacodynamic changes in several biomarkers, including increases in VEGF-A, PlGF, AXL, and GAS6 levels and decreases in VEGFR2 and HGF levels; these changes were not associated with OS or PFS. <b><i>Conclusion:</i></b> Cabozantinib improved OS and PFS versus placebo at high and low baseline concentrations for all biomarkers analyzed. Low baseline levels of MET, HGF, GAS6, IL-8, and ANG2 and high levels of IGF-1 were identified as potential favorable prognostic biomarkers for survival in previously treated advanced HCC. Although cabozantinib promoted pharmacodynamic changes in several biomarkers, these changes were not associated with survival." @default.
• W4200415204 created "2021-12-31" @default.
• W4200415204 creator A5000552659 @default.
• W4200415204 creator A5004699298 @default.
• W4200415204 creator A5006848714 @default.
• W4200415204 creator A5011174725 @default.
• W4200415204 creator A5013744957 @default.
• W4200415204 creator A5015598872 @default.
• W4200415204 creator A5019481117 @default.
• W4200415204 creator A5050625196 @default.
• W4200415204 creator A5056027619 @default.
• W4200415204 creator A5056468054 @default.
• W4200415204 creator A5060350068 @default.
• W4200415204 creator A5062593266 @default.
• W4200415204 creator A5065803904 @default.
• W4200415204 creator A5081273660 @default.
• W4200415204 creator A5082631947 @default.
• W4200415204 date "2021-12-03" @default.
• W4200415204 modified "2023-10-14" @default.
• W4200415204 title "Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma" @default.
• W4200415204 cites W1612634664 @default.
• W4200415204 cites W2005653452 @default.
• W4200415204 cites W2018683437 @default.
• W4200415204 cites W2019607817 @default.
• W4200415204 cites W2040970018 @default.
• W4200415204 cites W2056408500 @default.
• W4200415204 cites W2063086242 @default.
• W4200415204 cites W2068562114 @default.
• W4200415204 cites W2100945326 @default.
• W4200415204 cites W2102942095 @default.
• W4200415204 cites W2104630532 @default.
• W4200415204 cites W2109479504 @default.
• W4200415204 cites W2119190881 @default.
• W4200415204 cites W2155152791 @default.
• W4200415204 cites W2180157132 @default.
• W4200415204 cites W2237658240 @default.
• W4200415204 cites W2414943712 @default.
• W4200415204 cites W2509321007 @default.
• W4200415204 cites W2517771094 @default.
• W4200415204 cites W2542081802 @default.
• W4200415204 cites W2591717879 @default.
• W4200415204 cites W2727497670 @default.
• W4200415204 cites W2737941233 @default.
• W4200415204 cites W2762855963 @default.
• W4200415204 cites W2795488377 @default.
• W4200415204 cites W2801404544 @default.
• W4200415204 cites W2804309168 @default.
• W4200415204 cites W2809889937 @default.
• W4200415204 cites W2908573150 @default.
• W4200415204 cites W2914676498 @default.
• W4200415204 cites W2914835944 @default.
• W4200415204 cites W2944753420 @default.
• W4200415204 cites W2969743394 @default.
• W4200415204 cites W3029631869 @default.
• W4200415204 cites W3040096066 @default.
• W4200415204 doi "https://doi.org/10.1159/000519867" @default.
• W4200415204 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35222506" @default.
• W4200415204 hasPublicationYear "2021" @default.
• W4200415204 type Work @default.
• W4200415204 citedByCount "19" @default.
• W4200415204 countsByYear W42004152042021 @default.
• W4200415204 countsByYear W42004152042022 @default.
• W4200415204 countsByYear W42004152042023 @default.
• W4200415204 crossrefType "journal-article" @default.
• W4200415204 hasAuthorship W4200415204A5000552659 @default.
• W4200415204 hasAuthorship W4200415204A5004699298 @default.
• W4200415204 hasAuthorship W4200415204A5006848714 @default.
• W4200415204 hasAuthorship W4200415204A5011174725 @default.
• W4200415204 hasAuthorship W4200415204A5013744957 @default.
• W4200415204 hasAuthorship W4200415204A5015598872 @default.
• W4200415204 hasAuthorship W4200415204A5019481117 @default.
• W4200415204 hasAuthorship W4200415204A5050625196 @default.
• W4200415204 hasAuthorship W4200415204A5056027619 @default.
• W4200415204 hasAuthorship W4200415204A5056468054 @default.
• W4200415204 hasAuthorship W4200415204A5060350068 @default.
• W4200415204 hasAuthorship W4200415204A5062593266 @default.
• W4200415204 hasAuthorship W4200415204A5065803904 @default.
• W4200415204 hasAuthorship W4200415204A5081273660 @default.
• W4200415204 hasAuthorship W4200415204A5082631947 @default.
• W4200415204 hasBestOaLocation W42004152041 @default.
• W4200415204 hasConcept C121608353 @default.
• W4200415204 hasConcept C126322002 @default.
• W4200415204 hasConcept C142724271 @default.
• W4200415204 hasConcept C143998085 @default.
• W4200415204 hasConcept C185592680 @default.
• W4200415204 hasConcept C204787440 @default.
• W4200415204 hasConcept C207103383 @default.
• W4200415204 hasConcept C27081682 @default.
• W4200415204 hasConcept C2776694085 @default.
• W4200415204 hasConcept C2777802072 @default.
• W4200415204 hasConcept C2778019345 @default.
• W4200415204 hasConcept C2778820342 @default.
• W4200415204 hasConcept C2781064419 @default.
• W4200415204 hasConcept C2781197716 @default.
• W4200415204 hasConcept C44249647 @default.
• W4200415204 hasConcept C55493867 @default.
• W4200415204 hasConcept C71924100 @default.
• W4200415204 hasConcept C90924648 @default.

• next